Argitalpenak (293) Jose Maria Moraleda Jimenez argitalpenak

2024

  1. Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects

    Biomolecules, Vol. 14, Núm. 7, pp. 734

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

    Blood Reviews, Vol. 66

  4. Flow Cytometry as a New Accessible Method to Evaluate Diagnostic Osmotic Changes in Patients with Red Blood Cell Membrane Defects

    Biomedicines, Vol. 12, Núm. 7

  5. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  6. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

  7. Optimizing cryopreservation conditions for use of fucosylated human mesenchymal stromal cells in anti-inflammatory/immunomodulatory therapeutics

    Frontiers in Immunology, Vol. 15

  8. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma

    JAMA Oncology

  9. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis

    Bone Marrow Transplantation

  10. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  11. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355

  12. The nuclei of human adult stem cells can move within the cell and generate cellular protrusions to contact other cells

    Stem cell research & therapy, Vol. 15, Núm. 1, pp. 32

2023

  1. Amniotic Membrane Restores Chronic Wound Features to Normal in a Keratinocyte TGF-β-Chronified Cell Model

    International Journal of Molecular Sciences, Vol. 24, Núm. 7

  2. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

    Bone Marrow Transplantation, Vol. 58, Núm. 11, pp. 1182-1188

  3. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

  4. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  5. N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study

    Annals of Hematology, Vol. 102, Núm. 8, pp. 2069-2075

  6. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  7. Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis

    Stem Cell Research and Therapy, Vol. 14, Núm. 1

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100